BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 37020867)

  • 21. Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia.
    Timofeeva N; Ayres ML; Baran N; Santiago-O'Farrill JM; Bildik G; Lu Z; Konopleva M; Gandhi V
    Front Oncol; 2023; 13():1161254. PubMed ID: 37228498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BCL-2 Inhibitors, Present and Future.
    Ryan CE; Davids MS
    Cancer J; 2019; 25(6):401-409. PubMed ID: 31764121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Venetoclax in the Treatment of Chronic Lymphocytic Leukemia: Evidence, Expectations, and Future Prospects.
    Tariq S; Tariq S; Khan M; Azhar A; Baig M
    Cureus; 2020 Jun; 12(6):e8908. PubMed ID: 32742874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
    Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia.
    Vitale C; Ferrajoli A
    Expert Rev Hematol; 2020 Aug; 13(8):885-894. PubMed ID: 32700593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma.
    Thus YJ; Eldering E; Kater AP; Spaargaren M
    Leukemia; 2022 Sep; 36(9):2165-2176. PubMed ID: 35725771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment.
    Shen Y; Crassini K; Fatima N; O'Dwyer M; O'Neill M; Christopherson RI; Mulligan SP; Best OG
    Blood Adv; 2020 Oct; 4(20):5093-5106. PubMed ID: 33085757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Schieber M; Ma S
    Blood Lymphat Cancer; 2019; 9():9-17. PubMed ID: 32009829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL.
    Jayappa KD; Gordon VL; Morris CG; Wilson B; Shetty BD; Cios KJ; Arora PC; Isaac KM; Saha S; Bender TP; Williams ME; Portell CA; Weber MJ
    Blood Adv; 2021 Sep; 5(17):3497-3510. PubMed ID: 34432864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
    Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
    BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia.
    Aw A; Brown JR
    Leuk Lymphoma; 2017 Oct; 58(10):2287-2297. PubMed ID: 28482721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia.
    Iskierka-Jażdżewska E; Obracaj A; Urbaniak M; Robak T
    Curr Treat Options Oncol; 2022 Jun; 23(6):775-795. PubMed ID: 35357653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Venetoclax for the treatment of chronic lymphocytic leukemia.
    Gentile M; Petrungaro A; Uccello G; Vigna E; Recchia AG; Caruso N; Bossio S; De Stefano L; Palummo A; Storino F; Martino M; Morabito F
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1307-1316. PubMed ID: 28972395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Ibrutinib combined with CAR-T cells in the treatment of del (17p) chronic lymphocytic leukemia with BCL-2 inhibitor resistance: a case report and literature review].
    Gong JJ; Yin QS; Li MJ; Ai H; Wang Q; Chen L; Wei XD; Song YP
    Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):750-754. PubMed ID: 31648477
    [No Abstract]   [Full Text] [Related]  

  • 36. BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.
    Bojarczuk K; Sasi BK; Gobessi S; Innocenti I; Pozzato G; Laurenti L; Efremov DG
    Blood; 2016 Jun; 127(25):3192-201. PubMed ID: 27095788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.
    Thijssen R; Ter Burg J; Garrick B; van Bochove GG; Brown JR; Fernandes SM; Rodríguez MS; Michot JM; Hallek M; Eichhorst B; Reinhardt HC; Bendell J; Derks IA; van Kampen RJ; Hege K; Kersten MJ; Trowe T; Filvaroff EH; Eldering E; Kater AP
    Blood; 2016 Jul; 128(4):574-83. PubMed ID: 27235137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma.
    Zhang J; Lu X; Li J; Miao Y
    Biomark Res; 2022 Apr; 10(1):17. PubMed ID: 35379357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia.
    Gordon MJ; Danilov AV
    Ther Adv Hematol; 2021; 12():2040620721989588. PubMed ID: 33796237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T.
    Wiedmeier-Nutor J; Leis J
    Curr Treat Options Oncol; 2022 Jun; 23(6):904-919. PubMed ID: 35435617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.